Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - Viracta Therapeutics, Inc. | snss-ex311_285.htm |
| EX-10.4 - EX-10.4 - Viracta Therapeutics, Inc. | snss-ex104_328.htm |
| EX-10.5 - EX-10.5 - Viracta Therapeutics, Inc. | snss-ex105_329.htm |
| EX-10.3 - EX-10.3 - Viracta Therapeutics, Inc. | snss-ex103_327.htm |
| EX-10.6 - EX-10.6 - Viracta Therapeutics, Inc. | snss-ex106_330.htm |
| EX-31.2 - EX-31.2 - Viracta Therapeutics, Inc. | snss-ex312_286.htm |
| EX-32.1 - EX-32.1 - Viracta Therapeutics, Inc. | snss-ex321_287.htm |
| EX-10.7 - EX-10.7 - Viracta Therapeutics, Inc. | snss-ex107_331.htm |
| 10-Q - 10-Q - Viracta Therapeutics, Inc. | snss-10q_20160331.htm |
Exhibit 10.1
Non-Employee Director Compensation Information
Sunesis Pharmaceuticals, Inc. has established the following annual compensation for non-employee members of its board of directors as follows.
Cash Compensation:
Board member: $40,000
In addition, each non-employee member of the board of directors is eligible to receive:
Board Chair: $20,000
Audit Committee Chair: $20,000
Compensation Committee Chair: $15,000
Nominating Committee Chair: $7,500
Audit Committee member: $10,000
Compensation Committee member: $7,500
Nominating Committee member: $5,000
In addition, all non-employee directors are reimbursed for out-of-pocket expenses incurred in attending board of directors and committee meetings.
Equity Compensation:
Initial Grant—Number of options to purchase shares of common stock: 75,000
Annual Grant—Number of options to purchase shares of common stock: 40,000